ANI Pharma Inc ANIP

$71.71 +0.54 (0.76%)

Valuation

Market cap
1,748,935,000
Revenue TTM
$883,370,000
Net income TTM
$78,340,000
PE ratio
10.59
Forward PE
9.36
Profit margin
8.87%
Debt to equity
0.50

Trading

Volume
335,900
Avg volume
379,912
Day's range
$70.31 – $72.76
Shares out
22,970,000
Stochastic %K
36%
Beta
0.45
Analysts
Strong Sell
Price target
$102.80

Price

Company profile

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The comp...

Show more

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Phone
218 634 3500
Website
https://www.anipharmaceuticals.com
Address
210 Main Street West, Baudette, United States

Latest news

Stocktwits

Victor224 Oct 21, 11:31 AM
$ANIP According to letter from FDA dated on October 5, 2026, the sNDA submitted August 26, 2026 for Cortrophin-Zinc Hydroxide was approved. It covers all the indications that Purified Cortrophin Gel covers plus an additional 31 indications. There is no other Cortrophin-Zinc on the market, so it will take time to get coverageand acceptance by physicians. Just as ANIP has been expanding the indications they focus on for Purified Cortrophin Gel, ANIP will do the same for Cortrophin-Zinc. Link to FDA letler https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/009854Orig1s013ltr.pdf Link to FDA approved Label https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/009854s013lbl.pdf It will proably be announced leading into Q3 Earnings
1 replies
dachshund36 Oct 19, 11:29 AM
$ANIP https://investor.anipharmaceuticals.com/news-releases/news-release-details/ani-pharmaceuticals-announces-launch-duloxetine-delayed-release
0 replies
Rayvio_News_Filter Oct 12, 10:55 AM
$ANIP 🏥 ANI Pharmaceuticals, Inc. announced positive Phase 4 SYNCHRONICITY trial results showing statistically significant improvements in BCVA letter score and CST at 6 months, maintained at 24 months in patients with chronic NIU-PS. Actionable market event
1 replies
Victor224 Oct 9, 11:23 AM
$ANIP Maybe one day ANIP will show all the drugs in their pipeline. In the meantime it is a bargain. Pipleine includes. - Libigel - Possibility of becoming the first FDA approved female testoterone. Sitting on Certification to delay submitting results on large Libigel safety/efficacy study aa precursr to an NDA submission. - Cortophin Zinc Hydroxide - the second drug acquired in their deal with Merck in 2015. ANIP submitted a label change for the drug to the FDA showing their intent to bring it back to market just as they did with Purified Cortrophin Gel. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/009854s013lbl.pdf Inzirqo - Approved in 2025. Hopefully, they have gained traction in getting it covered.
1 replies
Dy2ski Sep 11, 1:13 PM
$ANIP Actually, a decent job by the CEO and even CFO Carey at yesterday's conference. But pretty clear an acquisition is all that they're thinking about, though which will most likely be dilutive as heck to common shareholders and is probably why the share price is and has been absolute garbage and just hit a 52 week low.
1 replies
dachshund36 Sep 1, 11:22 AM
$ANIP Very interesting post here from a couple weeks ago. Still 100% valid for ANIP, projecting how long until 20% yield. https://cavemanscreener.substack.com/p/my-new-godfather-metric-how-long
0 replies
Dy2ski Aug 24, 4:35 PM
$ANIP Henry Gosebruch. Pretty impressive BOD appointment today. At the very least, it certainly gives a more confidence, if indeed, *Business Development* is pending. Hmmmm...
1 replies
Victor224 Aug 17, 11:54 PM
$ANIP Hopefully, ANIP finally presents the long-term safety/efficacy results for the 3,656 participant Libigel trial at the FDA Public Meeting: Testosterone Use In Menopausal Women on September 17, 2026. https://www.fda.gov/consumers/womens-health-events/fda-public-meeting-testosterone-use-menopausal-women-09172026#event-information If so, I would not be surprised, if an announcement comes out before the meetings. Possibly at the Morgan Stanley 24th Annual Global Healthcare Conference taking place September 14–16, 2026. NOTE: In 2011, an unblinded review partway through the study, with 4,000 patient years of data collected, found that restoring testosterone in postmenopausal women at a higher risk of cardiovascular events reduced their risk by at least 70%. In 2015, they further discovered the risk of experiencing breast cancer events was reduced by an undisclosed amount.
2 replies